Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 111.97 Billion JPY | -17.15% |
| 2023 | 169.17 Billion JPY | 40.16% |
| 2022 | 120.7 Billion JPY | -12.83% |
| 2021 | 138.46 Billion JPY | 22.33% |
| 2020 | 113.18 Billion JPY | 15.31% |
| 2019 | 98.16 Billion JPY | -1.71% |
| 2018 | 99.87 Billion JPY | 8.97% |
| 2017 | 91.65 Billion JPY | 116.76% |
| 2016 | 42.28 Billion JPY | -39.67% |
| 2015 | 70.08 Billion JPY | 10.99% |
| 2014 | 63.14 Billion JPY | 19.4% |
| 2013 | 52.88 Billion JPY | 1.12% |
| 2012 | 52.29 Billion JPY | 14.6% |
| 2011 | 45.63 Billion JPY | -1.31% |
| 2010 | 46.24 Billion JPY | -7.84% |
| 2009 | 50.17 Billion JPY | 7.88% |
| 2008 | 46.51 Billion JPY | 4.31% |
| 2007 | 44.58 Billion JPY | 4.01% |
| 2006 | 42.86 Billion JPY | 7.16% |
| 2005 | 40 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 111.97 Billion JPY | -33.81% |
| 2024 Q1 | 29.61 Billion JPY | -33.74% |
| 2024 Q4 | 33.98 Billion JPY | 0.49% |
| 2024 Q3 | 33.82 Billion JPY | 6.91% |
| 2024 Q2 | 31.63 Billion JPY | 6.82% |
| 2023 Q1 | 28.79 Billion JPY | -15.27% |
| 2023 Q3 | 32.45 Billion JPY | -48.69% |
| 2023 FY | 169.17 Billion JPY | 40.16% |
| 2023 Q4 | 44.69 Billion JPY | 37.73% |
| 2023 Q2 | 63.24 Billion JPY | 119.64% |
| 2022 Q3 | 29.63 Billion JPY | 5.15% |
| 2022 Q2 | 28.18 Billion JPY | -1.22% |
| 2022 Q1 | 28.52 Billion JPY | -52.33% |
| 2022 Q4 | 33.98 Billion JPY | 14.69% |
| 2022 FY | 120.7 Billion JPY | -12.83% |
| 2021 Q1 | 24.8 Billion JPY | -27.39% |
| 2021 FY | 138.46 Billion JPY | 22.33% |
| 2021 Q3 | 28.1 Billion JPY | 9.34% |
| 2021 Q4 | 59.84 Billion JPY | 112.92% |
| 2021 Q2 | 25.7 Billion JPY | 3.63% |
| 2020 FY | 113.18 Billion JPY | 15.31% |
| 2020 Q4 | 34.16 Billion JPY | 23.94% |
| 2020 Q3 | 27.56 Billion JPY | 7.29% |
| 2020 Q1 | 25.76 Billion JPY | -9.34% |
| 2020 Q2 | 25.69 Billion JPY | -0.3% |
| 2019 Q4 | 28.42 Billion JPY | 29.25% |
| 2019 FY | 98.16 Billion JPY | -1.71% |
| 2019 Q1 | 23.44 Billion JPY | -14.8% |
| 2019 Q2 | 24.3 Billion JPY | 3.65% |
| 2019 Q3 | 21.99 Billion JPY | -9.51% |
| 2018 Q2 | 24.45 Billion JPY | 9.6% |
| 2018 FY | 99.87 Billion JPY | 8.97% |
| 2018 Q4 | 27.51 Billion JPY | 7.54% |
| 2018 Q3 | 25.59 Billion JPY | 4.65% |
| 2018 Q1 | 22.31 Billion JPY | -14.53% |
| 2017 FY | 91.65 Billion JPY | 116.76% |
| 2017 Q4 | 26.1 Billion JPY | 11.85% |
| 2017 Q3 | 23.34 Billion JPY | 9.04% |
| 2017 Q2 | 21.4 Billion JPY | 2.91% |
| 2017 Q1 | 20.8 Billion JPY | -14.16% |
| 2016 Q4 | 24.23 Billion JPY | 9.81% |
| 2016 Q2 | -23.32 Billion JPY | -220.79% |
| 2016 FY | 42.28 Billion JPY | -39.67% |
| 2016 Q1 | 19.3 Billion JPY | 1.35% |
| 2016 Q3 | 22.06 Billion JPY | 194.62% |
| 2015 FY | 70.08 Billion JPY | 10.99% |
| 2015 Q3 | 18.89 Billion JPY | 8.4% |
| 2015 Q1 | 14.7 Billion JPY | -27.93% |
| 2015 Q2 | 17.43 Billion JPY | 18.54% |
| 2015 Q4 | 19.05 Billion JPY | 0.81% |
| 2014 Q2 | 14.64 Billion JPY | 12.69% |
| 2014 Q3 | 15.09 Billion JPY | 3.06% |
| 2014 Q4 | 20.4 Billion JPY | 35.17% |
| 2014 FY | 63.14 Billion JPY | 19.4% |
| 2014 Q1 | 12.99 Billion JPY | -12.1% |
| 2013 Q1 | 12.38 Billion JPY | -17.59% |
| 2013 Q2 | 12.42 Billion JPY | 0.31% |
| 2013 Q3 | 13.28 Billion JPY | 6.91% |
| 2013 FY | 52.88 Billion JPY | 1.12% |
| 2013 Q4 | 14.78 Billion JPY | 11.31% |
| 2012 FY | 52.29 Billion JPY | 14.6% |
| 2012 Q4 | 15.03 Billion JPY | 17.28% |
| 2012 Q1 | 11.43 Billion JPY | -3.33% |
| 2012 Q3 | 12.81 Billion JPY | -1.54% |
| 2012 Q2 | 13.01 Billion JPY | 13.83% |
| 2011 Q1 | 11.03 Billion JPY | -10.4% |
| 2011 Q4 | 11.82 Billion JPY | 3.39% |
| 2011 FY | 45.63 Billion JPY | -1.31% |
| 2011 Q2 | 11.33 Billion JPY | 2.69% |
| 2011 Q3 | 11.44 Billion JPY | 0.97% |
| 2010 Q1 | 10.4 Billion JPY | -4.94% |
| 2010 FY | 46.24 Billion JPY | -7.84% |
| 2010 Q4 | 12.31 Billion JPY | 6.06% |
| 2010 Q2 | 11.91 Billion JPY | 14.43% |
| 2010 Q3 | 11.61 Billion JPY | -2.51% |
| 2009 FY | 50.17 Billion JPY | 7.88% |
| 2009 Q2 | 11.73 Billion JPY | 0.0% |
| 2009 Q3 | 11.07 Billion JPY | -5.63% |
| 2009 Q4 | 10.94 Billion JPY | -1.1% |
| 2008 FY | 46.51 Billion JPY | 4.31% |
| 2007 FY | 44.58 Billion JPY | 4.01% |
| 2006 FY | 42.86 Billion JPY | 7.16% |
| 2005 FY | 40 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | -278.569% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -555.925% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -5115.417% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -219588.438% |
| Novartis AG | 24.87 Billion USD | -350.215% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.053% |